136 related articles for article (PubMed ID: 9475770)
1. Finasteride to prevent morbidity from benign prostatic hyperplasia.
Wasson JH
N Engl J Med; 1998 Feb; 338(9):612-3. PubMed ID: 9475770
[No Abstract] [Full Text] [Related]
2. Finasteride in benign prostatic hyperplasia.
Verhamme KM; Bosch RJ; Sturkenboom MC
N Engl J Med; 2004 Mar; 350(13):1359-61; author reply 1359-61. PubMed ID: 15049034
[No Abstract] [Full Text] [Related]
3. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group.
McConnell JD; Bruskewitz R; Walsh P; Andriole G; Lieber M; Holtgrewe HL; Albertsen P; Roehrborn CG; Nickel JC; Wang DZ; Taylor AM; Waldstreicher J
N Engl J Med; 1998 Feb; 338(9):557-63. PubMed ID: 9475762
[TBL] [Abstract][Full Text] [Related]
4. Dutasteride vs finasteride: assessment of differences in acute urinary retention rates and surgical risk outcomes in an elderly population aged > or =65 years.
Fenter TC; Davis EA; Shah MB; Lin PJ
Am J Manag Care; 2008 May; 14(5 Suppl 2):S154-9. PubMed ID: 18611089
[TBL] [Abstract][Full Text] [Related]
5. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia.
McConnell JD; Roehrborn CG; Bautista OM; Andriole GL; Dixon CM; Kusek JW; Lepor H; McVary KT; Nyberg LM; Clarke HS; Crawford ED; Diokno A; Foley JP; Foster HE; Jacobs SC; Kaplan SA; Kreder KJ; Lieber MM; Lucia MS; Miller GJ; Menon M; Milam DF; Ramsdell JW; Schenkman NS; Slawin KM; Smith JA;
N Engl J Med; 2003 Dec; 349(25):2387-98. PubMed ID: 14681504
[TBL] [Abstract][Full Text] [Related]
6. Finasteride in benign prostatic hyperplasia.
Wysowski DK; Farinas E
N Engl J Med; 2004 Mar; 350(13):1359-61; author reply 1359-61. PubMed ID: 15044649
[No Abstract] [Full Text] [Related]
7. [A trial of the use of finasteride and terazosin in patients with benign prostatic hyperplasia].
Pushkar' DIu; Kosko DV; Loran OB; Kan IaD; Sapozhnikov IM; Tevlin KP
Urol Nefrol (Mosk); 1995; (4):32-5. PubMed ID: 7571199
[TBL] [Abstract][Full Text] [Related]
8. Medical management of benign prostatic hyperplasia--are two drugs better than one?
Vaughan ED
N Engl J Med; 2003 Dec; 349(25):2449-51. PubMed ID: 14681512
[No Abstract] [Full Text] [Related]
9. [Cost-effectiveness aspects of benign prostatic hyperplasia (BPH) therapy].
Lopatkin NA; Ziborova IV; Sivkov AV; Apolikhin OI
Urol Nefrol (Mosk); 1999; (1):22-6. PubMed ID: 11149340
[TBL] [Abstract][Full Text] [Related]
10. Re: an economic evaluation of doxazosin, finasteride and combination therapy in the treatment of benign prostatic hyperplasia.
DiSantostefano RL; Biddle AK; Lavelle JP
Can J Urol; 2005 Feb; 12(1):2508-9; author reply 2509-10. PubMed ID: 15777487
[No Abstract] [Full Text] [Related]
11. [5-alpha reductase inhibitors or alpha blockers? The combination brakes best prostatic hyperplasia].
MMW Fortschr Med; 2002 Oct; 144(44):56. PubMed ID: 12494605
[No Abstract] [Full Text] [Related]
12. [The long-term treatment of patients with benign prostatic hyperplasia using Proscar].
Lopatkin NA; Roilans PJ; Stoner E
Urol Nefrol (Mosk); 1996; (1):2-4. PubMed ID: 8659035
[TBL] [Abstract][Full Text] [Related]
13. [Drug treatment of benign prostatic hyperplasia].
Schmid HP
Praxis (Bern 1994); 1995 Sep; 84(39):1061-2. PubMed ID: 7481307
[No Abstract] [Full Text] [Related]
14. Finasteride: new indication. Benign prostatic hypertrophy: sexual disorders.
Prescrire Int; 2007 Aug; 16(90):147. PubMed ID: 17724838
[TBL] [Abstract][Full Text] [Related]
15. 5-Alpha reductase inhibition provides superior benefits to alpha blockade by preventing AUR and BPH-related surgery.
Boyle P; Roehrborn C; Harkaway R; Logie J; de la Rosette J; Emberton M
Eur Urol; 2004 May; 45(5):620-6; discussion 626-7. PubMed ID: 15082205
[TBL] [Abstract][Full Text] [Related]
16. Finasteride to evaluate the efficacy of dutasteride in the management of patients with lower urinary tract symptoms and enlarged prostate.
Ravish IR; Nerli RB; Amarkhed SS
Arch Androl; 2007; 53(1):17-20. PubMed ID: 17364459
[TBL] [Abstract][Full Text] [Related]
17. [The effect of 5-alpha-reductase inhibitors on benign prostatic hyperplasia].
Djavan B; McConnell J
Wien Med Wochenschr; 1996; 146(8):165-8. PubMed ID: 8767401
[TBL] [Abstract][Full Text] [Related]
18. [Efficacy of finasteride in the treatment of hematuria associated with benign prostatic hypertrophy].
Palou Redorta J; Gausa Gascon L; Salvador Bayarre J; Millán Rodríguez F; Segarra Tomás J; Villavicencio Mavrich H
Arch Esp Urol; 2002 Oct; 55(8):895-9. PubMed ID: 12455279
[TBL] [Abstract][Full Text] [Related]
19. The concentrations of the endogenous C19-steroids in hyperplastic prostatic tissue and the effect of finasteride treatment.
Hill M; Petrik R; Hampl R; Stárka L
Horm Metab Res; 1996 Oct; 28(10):562-4. PubMed ID: 8934217
[TBL] [Abstract][Full Text] [Related]
20. Chemoprevention of prostate cancer.
Walsh PC
N Engl J Med; 2010 Apr; 362(13):1237-8. PubMed ID: 20357287
[No Abstract] [Full Text] [Related]
[Next] [New Search]
